EMEA recommends new contraindications for toremifene (Fareston): long QT interval and related heart diseases
In a recent press release, EMEA made clear the new contraindications for the selective modulator (SERM) toremifene (Fareston): Completing the review of the available data during its 19-22 January 2009 meeting, the CHMP concluded that the benefits of Fareston are greater than its risks, but that its use should be restricted. The CHMP recommended that […]